Results 191 to 200 of about 46,383 (210)

Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study

Lancet, The, 2008
Jean-Michel Molina
exaly  

Lopinavir/ritonavir

Reactions Weekly, 2017
openaire   +2 more sources

Ritonavir-boosted lopinavir plus nucleoside or nucleotide reverse transcriptase inhibitors versus ritonavir-boosted lopinavir plus raltegravir for treatment of HIV-1 infection in adults with virological failure of a standard first-line ART regimen (SECOND-LINE): a randomised, open-label, non-inferiority study

Lancet, The, 2013
Stephen J Kerr
exaly  

Lopinavir.

2011
openaire   +1 more source

Lopinavir/ritonavir

Reactions Weekly, 2018
openaire   +1 more source

Lopinavir/ritonavir

Reactions Weekly, 2023
openaire   +1 more source

Lopinavir

2016
openaire   +1 more source

Nevirapine versus Ritonavir-Boosted Lopinavir for HIV-Infected Children

New England Journal of Medicine, 2012
Avy Violari, Hilda A Mujuru, Mark F Cotton   +2 more
exaly  

Modified pullulan nanoparticles for oral delivery of lopinavir: Formulation and pharmacokinetic evaluation

Carbohydrate Polymers, 2014
Punna Rao Ravi, Rahul Vats
exaly  

Lopinavir/ritonavir

Reactions Weekly, 2016
openaire   +2 more sources